MedTech Science and Innovation Day
Datum
-
Plats
Arr: Uppsala universitet, Uppsala
Appreciated premiere for KI Science Park Lunch Talks
This is a new, open meeting spot for the life science sector in and around Hagastaden, and the first meeting was fully booked. The goal is to stimulate conversations and exchanges around current themes that affect many people from different perspectives.
"All organizations can benefit from getting their offer analysed"
Peter Löwenhielm works as a business coach at KI Innovations, an innovation office and incubator that helps in the entire innovation process from idea to market. The goal is that more research-based ideas, discoveries, and knowledge from Karolinska Institutet can contribute to a healthier future for all.
The Swedish healthcare system: education day
Datum
-
Plats
Arr: Forum för Health Policy, Webbinarium
Digitalization in Swedish healthcare, where are we aiming?
-
The digitalization of Swedish healthcare is making progress. With Vision for e-health 2025, the government, together with authorities, regions, and municipalities, has set the goal that Sweden should be world-leading at "using the opportunities offered by digitization and e-health to make it easier for people to achieve good and equal health and welfare, and to develop and strengthen their own resources for increased independence and participation in the life of society.”
Welcome to a seminar that shed light on the development of e-health in Sweden today.
Unique methodology for investments in Life Science
There is a growing interest in investing in startups. But analyzing the market is complex, and the need for competence at the companies varies greatly. Forty experienced entrepreneurs have now formed Scale Up Life Science Invest, which invests smart capital in early stage startups.
Is it possible to change the negative trend for clinical trials in Sweden?
We have a strong and competitive pharmaceutical pipeline here! It's with pride and joy that I read the report "The Swedish Drug Discovery and Development Pipeline 2023", released by SwedenBIO earlier in March. But of the 74 companies that filled in the survey, 68 percent conduct their clinical trials outside Sweden. Only 19 percent of the companies do their tests primarily in Sweden, and 14 percent do both abroad and at home.
"Exciting to follow the development of ideas into companies"
In December, Johan Weigelt became CEO of KI Holding. Two months later also CEO at KI Innovations. Being involved in and supporting the development of products that improve people's health and save lives is something he appreciates.
The Swedish Drug Discovery and Development Pipeline Report 2023
The report by SwedenBIO contains a mapping of the pharmaceutical pipeline run by companies headquartered in Sweden. The target group for the report includes international investors, the life science industry in Sweden and of course decision makers within politics, business and academia. The aim of the report is to be a basis for fact-based improvements of the industry and to promote Sweden’s position in pharmaceutical development.